Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
| ▸ | DRD5 | P21918 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 10/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22953005 | 0.86 | ADRA2A (0.39) | ADRA2ADRD2ADRA2BADRA2CDRD1 | |
| SCHEMBL22952931 | 0.81 | DRD1 (0.60) | ADRA2ADRD2ADRA2BADRA2CDRD1 | |
| SCHEMBL22953006 | 0.78 | HTR2C (0.36) | ADRA2ADRD2ADRA2BADRA2CDRD1 | |
| SCHEMBL22952935 | 0.74 | DRD1 (0.54) | ADRA2ADRD2ADRA2BADRA2CDRD1 | |
| SCHEMBL22952999 | 0.68 | ADRA2A (0.45) | ADRA2ADRD2ADRA2BADRA2CDRD1 | |
| SCHEMBL22953001 | 0.65 | ADRA2A (0.37) | ADRA2ADRD2ADRA2BADRA2CDRD1 | |
| SCHEMBL22952956 | 0.64 | DRD1 (0.52) | ADRA2AADRA2BADRA2CDRD1HTR2C | |
| SCHEMBL22952997 | 0.64 | ADRA2A (0.45) | ADRA2ADRD2ADRA2BADRA2CDRD1 | |
| SCHEMBL23214900 | 0.58 | CHRNB2 (0.48) | HTR2C | |
| SCHEMBL23239260 | 0.58 | CHRNB2 (0.48) | HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021021922-A1 | COMPOUNDS AND METHODS FOR TREATING FIBROTIC PATHOLOGIES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2021-02-04 | — | — | WO | disclosed |